Pamela L. Barnes

I attribute my success to three things that have shaped every meaningful outcome in my career.

The first is relationships. Federal policy work is fundamentally relational. The engagement that secured PREP Act liability protections at GSK was possible because of direct working relationships with HHS General Counsel. The Tri-Caucus Foundation engagement at Bristol Myers Squibb that produced a nationally broadcast CBCF policy session and secured C-SPAN coverage was built on years of trust with Members of Congress, Hill staff, and community partners. Those relationships were not transactional. They were built over time, sustained through consistent follow-through, and drawn on only when the moment required them.

The second is understanding how decisions actually get made. Federal rules are shaped long before they publish, through meetings that never generate a public record and through coalitions that form quietly. Knowing that architecture is what separates episodic engagement from strategic engagement.

The third is judgment under pressure. Some of my most consequential work happened in high-stakes moments: pandemic-era regulatory strategy, cross-functional crisis response during the Russia-Ukraine conflict, and coordinating enterprise policy positions during periods of intense federal reform. Judgment matters most when the environment gives you no time to develop it.

These three things are the foundation ELM Capitol Group is built on, and the standard I hold myself to in every client engagement.

Early in my career at HHS, a senior colleague told me: "The decisions that matter are made in the room before the rule is written. Your job is to be in that room."

At the time, I understood it as a lesson about access and preparation. Over the years, I've come to see it as the entire architecture of federal policy work. By the time a proposed rule appears in the Federal Register, the substantive direction has usually been set months earlier through meetings that don't generate a public record, coalition positions that quietly formed, and technical language shaped by career staff whose names most people outside government will never know.

That advice shaped how I built my practice. It's why I treat federal engagement as a continuous discipline rather than a comment-window exercise. It's why relationships and consistent presence matter more than any single letter or briefing. And it's why I built ELM Capitol Group on the premise that CMS and other federal agencies should be treated as strategic enterprise accounts, engaged proactively, before the decisions are made.

The federal health policy environment is in the most active period of restructuring in a generation. What that means in practice is that the rules governing how medicines get paid for, who has access to them, and how quickly innovation reaches patients are being rewritten in real time. Biopharma companies, hospitals, and patient advocacy organizations are being asked to keep up with a pace few are structurally prepared for.

The most immediate challenge is the implementation of the Inflation Reduction Act, the 2022 law that gave Medicare authority to negotiate prices for a growing number of prescription drugs. On June 12, 2026, the Centers for Medicare and Medicaid Services (CMS) released its first proposed rule to implement the drug price negotiation program through formal rulemaking. Comments from the public are due August 17, 2026. This rule will shape which drugs are eligible for negotiation, how future formulations are treated, and how small biotech innovators are protected. For patients, the outcome determines what they pay at the pharmacy counter and which therapies remain commercially viable to develop in the first place.

The second major challenge is 340B, a federal drug pricing program that requires manufacturers to sell certain medicines at discounted prices to hospitals and clinics serving low-income and vulnerable patients. The program is under active restructuring on several fronts: how discounts are delivered, how duplicate discounts between programs are prevented, and how much Medicare pays hospitals for these drugs. On July 2, 2026, CMS proposed cutting Medicare payments to 340B hospitals by nearly 40%. Every one of these changes has real consequences for whether safety-net hospitals can keep their doors open and whether the patients who depend on them can access their medicines.

The third challenge is the pace itself. Drug price negotiation, 340B restructuring, pharmacy benefit manager reform, most-favored-nation pricing developments, and state-level activity are all moving in parallel. Most organizations are engaging reactively, one comment deadline at a time. Meanwhile, patients wait.

The opportunity, and where I see hope, is for organizations willing to operate differently. Rules are shaped long before they publish, through meetings that never generate a public record and through coalitions that form quietly. The organizations that engage well, biopharma, patient advocacy groups, trade associations, hospitals, community health organizations, are the ones that treat federal agencies as strategic partners, engaged early and coordinated internally across every function that touches policy. When that happens, the patient at the end of the policy is the one who benefits.

That is the work ELM Capitol Group was built to do.